
Commentary|Videos|March 25, 2026
The Emergence of Bispecific Antibodies in Lymphoma
Author(s)Jennifer E. Amengual, MD
Fact checked by: Paige Britt
Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into clinical trials.
In an interview with Targeted Oncology, Jennifer Amengual, MD, Herbert Irving associate professor of Medicine in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discusses the emergence of bispecific antibodies and how that effects epigenetic therapy in lymphoma treatment.




























